The Saarbrücken-based DHC Business Solutions supports the digitalization of quality and compliance management at 4TEEN4 Pharmaceuticals GmbH from Hennigsdorf near Berlin with its start-up program VENTURES. The integrated management system DHC VISION provides 4TEEN4 with a regulatory compliant digital solution for the control of its research-related processes and future clinical trials.
Digital quality and compliance processes
4TEEN4 Pharmaceuticals GmbH is working on an innovative therapeutic solution for patients with an uncontrolled release of Dipeptidyl Peptidase 3 (DPP3) into the bloodstream. DPP3 is a biomarker that is strongly associated with short-term organ dysfunction, such as cardiogenic shock. At the same time, DPP3 is also a drug-treatable target. 4TEEN4 is developing the monoclonal therapeutic antibody procizumab in combination with targeted diagnostic tests. Currently, 4TEEN4 is preparing for clinical trials with the antibody and has relied on digital processes in quality and compliance management from the very beginning. The basis for this is provided by the integrated management system DHC VISION, which was introduced at the Brandenburg biotech company as part of the VENTURES funding program.
Ventures enables start-ups to enter the digital world of quality management
“With VENTURES we want to enable start-ups and young companies to enter the digital world of quality and compliance management,” emphasizes Dr. Wolfgang Kraemer, Managing Director and shareholder at DHC Business Solutions. “Especially in the early phases of corporate development, the digitalization of processes is still relatively easy, even though the regulatory requirements are high. This helps avoid complex change processes at a later stage. So 4TEEN4 does everything right here”. In the context of VENTURES, startups and young enterprises receive the software DHC VISION without license costs and to special conditions for services and system operation. Also, the complete documentation for the required validation (CSV) of the software is provided free of charge.
About 4TEEN4 Pharmaceuticals GmbH
The biopharmaceutical company 4TEEN4 Pharmaceuticals GmbH is developing procizumab, a humanized antibody directed against human dipeptidyl peptidase 3 (DPP3) for the treatment of acute cardiovascular diseases. 4TEEN4 licensed the diagnostic rights for DPP3 as an acute medical biomarker for organ dysfunction to SpingoTec GmbH. 4TEEN4 was founded in 2013 in Hennigsdorf near Berlin by Dr. Andreas Bergmann, CEO of 4TEEN4, as part of his Medicine4Future initiative. Further information about the company can be found at https://4teen4.de/.